At a glance
- Originator Spectrum Pharmaceuticals
- Developer Assertio Therapeutics
- Class Obesity therapies
- Mechanism of Action Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Major depressive disorder; Obesity
Most Recent Events
- 29 Dec 2000 Discontinued-Preclinical for Depression in USA (Unknown route)
- 29 Dec 2000 Discontinued-Preclinical for Obesity in USA (Unknown route)
- 12 May 2000 Preclinical development for Depression in USA (Unknown route)